Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · IEX Real-Time Price · USD
2.120
-0.050 (-2.30%)
Mar 18, 2024, 4:00 PM EDT - Market closed

Aadi Bioscience Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Cash & Equivalents
62.8939.02148.994.4638.5662.6520.291.630.02
Short-Term Investments
45.96133.54000000.050
Cash & Cash Equivalents
108.85172.56148.994.4638.5662.6520.291.680.02
Cash Growth
-36.92%15.82%3244.31%-88.45%-38.45%208.87%1106.97%8970.40%-
Receivables
5.491.86014.1500000
Inventory
6.431.860000000
Other Current Assets
3.833.752.280.081.011.330.610.540
Total Current Assets
124.59180.03151.2718.6939.5763.9820.92.230.02
Property, Plant & Equipment
5.972.030.610.140.330.10.110.150
Goodwill and Intangibles
003.81000000
Other Long-Term Assets
1.872.182.2100.040.040.020.020
Total Long-Term Assets
7.844.216.640.140.370.140.130.170
Total Assets
132.42184.24157.9118.8339.9464.1221.032.40.02
Accounts Payable
5.99.2812.216.713.235.463.592.470
Current Debt
0.430.390.139.150.10012.390.16
Other Current Liabilities
20.069.172.954.200000.04
Total Current Liabilities
26.418.8415.2730.063.335.463.5914.860.21
Long-Term Debt
0.831.270.471.10.070000
Other Long-Term Liabilities
05.765.760.100073.760
Total Long-Term Liabilities
0.837.026.231.20.070073.760
Total Liabilities
27.2325.8621.531.263.45.463.5988.620.21
Total Debt
1.271.660.6110.260.170012.390.16
Debt Growth
-23.72%174.55%-94.10%5933.19%---7641.65%-
Retained Earnings
-268.96-203.2-142.69-32.6-142.24-118.96-108.56-86.22-0.24
Comprehensive Income
0.03-0.120000000
Shareholders' Equity
105.2158.38136.41-12.4336.5458.6717.44-86.22-0.19
Net Cash / Debt
107.58170.9148.38-5.838.3962.6520.29-10.71-0.14
Net Cash / Debt Growth
-37.05%15.17%---38.72%208.87%---
Net Cash Per Share
4.007.5916.63-2.2814.1927.7014.04-188.34-0.42
Working Capital
98.19161.19136-11.3736.2458.5317.31-12.63-0.19
Book Value Per Share
3.917.0415.29-4.8913.5025.9312.07-1516.74-0.56
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).